Indian stocks: Visit www.stage2stocks.com →

Rein Therapeutics, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, Rein Therapeutics is in Stage 4, the downtrend phase, now in week 20 (since Jun 8, 2026). It closed at $0.60, 68.0% below its 52-week high and below its 200-day average, which is falling.

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. More about the company

$0.60
-2.67% today
$52.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RNTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 22w
S4 26w
S4 16w
S4 20w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 13w → S1 1w → S2 22w → S3 8w → S4 12w → S1 10w → S4 26w → S1 4w → S4 16w → S1 11w → S4 11w → S1 3w → S2 4w → S3 2w → S4 20w current
Total tracked: 164 weeks across 16 stage runs.

RNTX among Biotechnology362nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…362RNTXStage 4 · wk 2022−21.8%
vs 52W High
-68.0%
$0.55 lo$1.88 hi
68.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 20
1w13w26w
Week 20, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-42.9%
200 DMA: $1.05 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.69x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.8%
3M
-23.9%
6M
-67.3%
YTD
-51.8%
1Y
-53.0%
Scan Membership
Breakout Watch
Latest: 2023-12-08
4 appearances in last 60 days. First seen: 2020-02-27.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 20 · Vol 0.69x
2026-10-21S4
Wk 19 · Vol 0.60x
2026-10-20S4
Wk 19 · Vol 0.66x
2026-10-19S4
Wk 19 · Vol 1.13x
2026-10-16S4
Wk 19 · Vol 0.85x
2026-10-15S4
Wk 19 · Vol 3.16x
2026-10-14S4
Wk 18 · Vol 2.71x
2026-10-13S4
Wk 18 · Vol 0.34x
2026-10-12S4
Wk 18 · Vol 0.25x
2026-10-09S4
Wk 18 · Vol 0.72x
2026-10-08S4
Wk 18 · Vol 1.14x
2026-10-07S4
Wk 17 · Vol 1.05x
Moving averages & range
50 DMA
$0.76
200 DMA
$1.05
52W High
$1.88
52W Low
$0.55
5D Low
$0.55
Resistance levels (recent highs)
20d High
$0.85
60d High
$0.89
120d High
$1.22
250d High
$1.88
Next resistance
+41.5%
to 20d High
ROE
-96.4%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 5.1

Rein Therapeutics: quick answers

What stage is Rein Therapeutics in?

As of Oct 22, 2026, Rein Therapeutics (RNTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 8, 2026 and is in week 20. What the four stages mean

Is Rein Therapeutics in an uptrend?

No. Rein Therapeutics is in a Stage 4 downtrend. It trades 42.9% below its 200-day average, which is falling.

How far is Rein Therapeutics from its 52-week high?

Rein Therapeutics closed at $0.60 on Oct 22, 2026, 68.0% below its 52-week high of $1.88. Its 52-week low is $0.55.

How has Rein Therapeutics performed over the past year?

As of Oct 22, 2026, Rein Therapeutics is down 53.0% over the past year and down 51.8% so far in 2026.

Which sector and industry is Rein Therapeutics in?

Rein Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.